Kessler's doubts

BIO's rebuttal

WASHINGTON - Former FDA Commissioner David Kessler's comments last week on drug prices and the FDA's ability to regulate cloning brought a rebuff from the Biotechnology Industry Organization.

Regarding Kessler's suggestions that FDA lacked the regulatory framework or resources to regulate cloning, BIO President Carl Feldbaum said: "I disagree categorically. They have the authority, and we hope that HHS Secretary Donna Shalala uses a substantial part of her discretionary